Phosphine–copper(I) complexes as anticancer agents: design, synthesis, and physicochemical characterization. Part I
Authors:
- 26 April 2019
- book chapter
- Published by Elsevier
- p. 61-82
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsChemical Reviews, 2016
- Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and FutureThe Oncologist, 2015
- A molecular view of cisplatin's mode of action: interplay with DNA bases and acquired resistancePhysical Chemistry Chemical Physics, 2015
- Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we knowJournal of the Peripheral Nervous System, 2014
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Metal-based antitumour drugs in the post genomic eraDalton Transactions, 2006
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004